biofilm formation – Page 3

New Strategies to Combat Human Fungal Infections

mycolabadmin

Fungal infections are becoming a major global health threat, causing millions of deaths annually. This research collection presents new and improved ways to treat these infections, including natural compounds like chitosan, beneficial bacteria, new drug combinations, and tests to better understand which treatments work best. The papers showcase innovative approaches beyond traditional antifungal medications to help combat resistant infections.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Impact of Clove Oil on Biofilm Formation in Candida albicans and Its Effects on Mice with Candida Vaginitis

mycolabadmin

Clove oil, a common kitchen spice, shows promise as a treatment for vaginal yeast infections caused by Candida albicans. The oil contains eugenol, which blocks the fungus’s ability to form protective biofilms and reduces inflammation. In mouse studies, clove oil treatment decreased yeast infection symptoms and lowered inflammatory markers, suggesting it could be a safe, natural alternative to conventional antifungal drugs.

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

mycolabadmin

Researchers studied how Trikafta, a new cystic fibrosis medication, affects Aspergillus fungus growth. While Trikafta doesn’t directly kill the fungus, it makes antifungal drugs more effective and improves patients’ lung function to help clear infections naturally. However, high concentrations of the drug may reduce the immune system’s ability to fight the fungus, suggesting careful monitoring of patients is needed.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health threat, especially for people with weakened immune systems, causing millions of deaths annually. Currently available antifungal drugs are limited and increasingly face resistance, making them less effective over time. This special collection of research papers explores new approaches to treating fungal infections, including novel drugs, combination therapies, and alternative treatments to overcome resistance. Scientists and doctors hope these advances will help save more lives by providing better options for treating serious fungal diseases.

Interaction with amoeba drives virulence-associated phenotypes in the Candida haemulonii complex

mycolabadmin

Researchers discovered that when fungal pathogens called Candida haemulonii are exposed to soil amoebae in laboratory conditions, they develop enhanced disease-causing abilities. These fungi undergo multiple changes including forming stronger protective biofilms, producing more virulence factors, and becoming harder to kill by immune defenses. This suggests that fungal pathogens might develop some of their dangerous traits not from infecting humans, but from surviving in soil environments where they must evade predatory organisms like amoebae.

Antifungal persistence: Clinical relevance and mechanisms

mycolabadmin

Some fungal infections don’t respond well to antifungal medications even though the fungi aren’t drug-resistant. This happens because a small percentage of fungal cells enter a dormant, low-energy state that protects them from being killed by the drugs. Understanding how these persistent cells survive and finding ways to target them could help prevent recurring fungal infections and improve treatment outcomes.

Identification of fungal agents isolated from burn lesions using mycological and molecular methods in patients admitted to Velayat burn hospital in Rasht city during 2022–2023

mycolabadmin

Researchers studied fungal infections in burn patients at a hospital in Iran and found that non-albicans Candida fungi, particularly a species called Candida parapsilosis, were the most common culprits. Using laboratory cultures and genetic testing, they identified 101 fungal infections out of 380 burn patients. Understanding which fungi cause these infections is important for doctors to choose the right treatment and improve patient outcomes.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection on his replacement heart valve after recent surgery. The fungal infection was caused by a type of yeast called Candida glabrata that was resistant to the initial antifungal medication. After testing revealed resistance and biofilm formation, doctors switched to caspofungin, a stronger antifungal drug, and the patient recovered successfully.

Do farnesol and tyrosol production in Candidozyma auris biofilms reflect virulence potential?

mycolabadmin

Researchers discovered that a dangerous fungus called Candidozyma auris produces signaling molecules called farnesol and tyrosol in biofilms. These molecules appear to be linked to how dangerous the fungus is—strains that produce more of these molecules were more virulent in infection studies. Understanding these signaling molecules could help develop new strategies to fight this drug-resistant pathogen.

Research Keyword: biofilm formation